EC
ASMB icon

EntryPoint Capital’s Assembly Biosciences ASMB Stock Holding History

EntryPoint Capital’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$228K Sell
8,285
-4,099
-33% -$112K 0.06% 648
2026
Q1 		$344K Buy
+12,384
New +$353K 0.1% 410

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

EntryPoint Capital's ASMB Position: Q2 2026 in Review

EntryPoint Capital reduced its Assembly Biosciences (ASMB) stake by 33% in Q2 2026, selling an estimated $112K and leaving 8,285 shares worth $228K. The position accounts for 0.06% of the portfolio, ranked #648.

EntryPoint Capital first reported a position in ASMB in Q1 2026 and has held it in 2 quarters since. The position peaked at $344K in Q1 2026. 93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • EntryPoint Capital held 8,285 shares of Assembly Biosciences worth $228K as of Q2 2026.
  • EntryPoint Capital sold 4,099 Assembly Biosciences shares in Q2 2026, an estimated $112K.
  • Assembly Biosciences made up 0.06% of EntryPoint Capital's portfolio in Q2 2026, its #648 holding.
  • EntryPoint Capital first reported a position in Assembly Biosciences in Q1 2026 and has held it in 2 quarters since.
  • EntryPoint Capital's Assembly Biosciences position peaked at $344K in Q1 2026.
  • 93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.